search
Back to results

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

Primary Purpose

Traumatic Brain Injury

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
autologous bone marrow mononuclear cells
Placebo Infusion
Sponsored by
The University of Texas Health Science Center, Houston
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Traumatic Brain Injury focused on measuring Traumatic Brain Injury, TBI, pediatric, acute, stem cells

Eligibility Criteria

5 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Between 5 and 17 years of age on the day of injury,
  2. Glasgow Coma Score (GCS) between 3 and 8, (best un-medicated post-resuscitation score during screening),
  3. Ability to obtain legally authorized representative (LAR) consent, and complete the BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury,
  4. Ability to speak English or Spanish.

Exclusion Criteria:

  1. Known history of: a. previous brain injury, b. intellectual deficiency or psychiatric condition, defined as inability to independently function in a regular classroom that may invalidate our ability to assess post-injury changes in cognition or behavior (ADHD and/or other learning disabilities are NOT an exclusion), c. neurologic impairment and/or deficit, d. seizure disorder requiring anti-convulsant therapy, e. recently treated infection, f. renal disease or altered renal function (post-resuscitation serum creatinine > 1.5 mg/dL), g. hepatic disease or altered liver function (post-resuscitation, non-contusion related SGPT > 150 μ/L and/or T. Bilirubin >1.3 mg/dL), h. cancer, i. immunosuppression as defined by WBC < 3, 000 cells/ml at admission, j. HIV+, k. chemical or ETOH dependency, l. history of child abuse, m. premature birth (<37 weeks GA/2500 grams) resulting in cognitive/physical disabilities and/or developmental delay.
  2. Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged hypoxic ischemic insult/herniation syndrome.
  3. Initial hospital ICP > 40 mm Hg.
  4. Hemodynamic instability at the time of screening defined as SBP <90 mmHg, ongoing fluid resuscitation and/or requirement for inotropic support to maintain MAP at or above normal for age - does not include CPP based inotropic support. IVF alone does not exclude from enrollment.
  5. Uncorrected coagulopathy at the time of bone marrow harvest defined as INR > 1.6, PTT > 38 sec; PLT< 100,000; Fibrinogen < 100 g/dL.
  6. Unstable pelvic fractures defined as requiring early operative fixation.
  7. Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and/or PaO2:FiO2 ratio < 250 associated with the mechanism of injury.
  8. Greater than AAST Grade 3 solid or hollow visceral injury of the abdomen and/or pelvis as diagnosed by CT or other imaging.
  9. Spinal cord injury diagnosed by CT/MR imaging or clinical findings.
  10. Persistent hypoxia defined as SaO2 < 94% for > 30 minutes occurring at any time from hospital admission to time of consent.
  11. Positive pregnancy test, if applicable.
  12. Concurrent participation in an interventional drug/device research study.
  13. Unwillingness to return for follow-up visits.
  14. Contraindications to MRI.
  15. Penetrating brain injury.

Sites / Locations

  • Phoenix Children's Hospital I University of Arizona
  • The University of Texas Health Science Center at Houston

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

autologous bone marrow mononuclear cells

placebo infusion

Arm Description

a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.

a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.

Outcomes

Primary Outcome Measures

brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI)
DTMRI quantitative indices of both macro and microscopic integrity will be evaluated and compared to DTMRI of immediate post-injury treated and non-treated controls.

Secondary Outcome Measures

CNS white matter and gray matter preservation in regions of interest and improves functional and neurocognitive deficits in children after TBI

Full Information

First Posted
May 5, 2013
Last Updated
November 19, 2020
Sponsor
The University of Texas Health Science Center, Houston
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT01851083
Brief Title
Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury
Official Title
A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
August 2013 (undefined)
Primary Completion Date
September 16, 2020 (Actual)
Study Completion Date
October 12, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The University of Texas Health Science Center, Houston
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pediatric severe traumatic brain injury (TBI) is the leading cause of death and disability in children ages 1-14 years old. There are no effective therapies to treat secondary brain injury and the post-injury response of CNS apoptosis and neuroinflammation. This study is a follow-up trial from a previously performed Phase I trial that demonstrated the safety and potential CNS structural preservation effect of intravenous autologous bone marrow mononuclear cells (BMMNC) after severe TBI in children. (Cox, 2011) The study is designed as a prospective, randomized, placebo controlled, blinded Phase 2 safety/biological activity study. The investigators hope to determine the effect of intravenous infusion of autologous BMMNCs on brain structure and neurocognitive/functional outcomes after severe TBI in children.
Detailed Description
Study Design: Multicenter, randomized, blinded, placebo controlled, Bayesian adaptive dose escalation design. Study Intervention: Single dose administered within 48 hours from time of injury. Controls will undergo a sham harvest and receive similarly labeled/external appearance and volume of 0.9% NaCl. BMMNC's will be harvested and undergo processing under cGMP conditions to obtain 6x10^6 cells/kg or 10x10^6 cells/kg weight. The cellular product/placebo will be infused within 48 hours of injury. Safety Monitoring & Follow-Up: Subjects will be monitored for infusion related toxicity post-infusion through hospital discharge and follow-up return study visits. Laboratory and imaging studies will be repeated at the 1, 6, and 12-month follow-up visits. A medical safety monitor (MSM) will review blinded SAE reports following post-infusion Day 14 for each subject in real time to ensure good clinical practice and to quickly identify safety concerns. The MSM will remain blinded to the treatment assignment, unless the NINDS appointed DSMB approves unblinding.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Traumatic Brain Injury
Keywords
Traumatic Brain Injury, TBI, pediatric, acute, stem cells

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
47 (Actual)

8. Arms, Groups, and Interventions

Arm Title
autologous bone marrow mononuclear cells
Arm Type
Experimental
Arm Description
a bone marrow harvest will be performed, followed by a single intravenous infusion of autologous bone marrow mononuclear cells within 48 hours of injury.
Arm Title
placebo infusion
Arm Type
Placebo Comparator
Arm Description
a sham harvest will be performed, followed by a single intravenous placebo infusion within 48 hours of injury.
Intervention Type
Biological
Intervention Name(s)
autologous bone marrow mononuclear cells
Other Intervention Name(s)
BMMNCs
Intervention Description
BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
Intervention Type
Other
Intervention Name(s)
Placebo Infusion
Other Intervention Name(s)
Saline Infusion
Intervention Description
Placebo infusion of 0.9% Sodium Chloride
Primary Outcome Measure Information:
Title
brain white matter and gray matter structural preservation on diffusion tensor magnetic resonance imaging (DTMRI)
Description
DTMRI quantitative indices of both macro and microscopic integrity will be evaluated and compared to DTMRI of immediate post-injury treated and non-treated controls.
Time Frame
one year post infusion
Secondary Outcome Measure Information:
Title
CNS white matter and gray matter preservation in regions of interest and improves functional and neurocognitive deficits in children after TBI
Time Frame
one year post infusion
Other Pre-specified Outcome Measures:
Title
Infusional toxicity safety evaluations
Description
Murray Score and liver function tests
Time Frame
7 days post-infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
5 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Between 5 and 17 years of age on the day of injury, Glasgow Coma Score (GCS) between 3 and 8, (best un-medicated post-resuscitation score during screening), Ability to obtain legally authorized representative (LAR) consent, and complete the BMMNC/Sham harvest and cell/placebo infusion within 48 hours of the initial injury, Ability to speak English or Spanish. Exclusion Criteria: Known history of: a. previous brain injury, b. intellectual deficiency or psychiatric condition, defined as inability to independently function in a regular classroom that may invalidate our ability to assess post-injury changes in cognition or behavior (ADHD and/or other learning disabilities are NOT an exclusion), c. neurologic impairment and/or deficit, d. seizure disorder requiring anti-convulsant therapy, e. recently treated infection, f. renal disease or altered renal function (post-resuscitation serum creatinine > 1.5 mg/dL), g. hepatic disease or altered liver function (post-resuscitation, non-contusion related SGPT > 150 μ/L and/or T. Bilirubin >1.3 mg/dL), h. cancer, i. immunosuppression as defined by WBC < 3, 000 cells/ml at admission, j. HIV+, k. chemical or ETOH dependency, l. history of child abuse, m. premature birth (<37 weeks GA/2500 grams) resulting in cognitive/physical disabilities and/or developmental delay. Obliteration of perimesencephalic cistern on initial head CT/MRI suggesting prolonged hypoxic ischemic insult/herniation syndrome. Initial hospital ICP > 40 mm Hg. Hemodynamic instability at the time of screening defined as SBP <90 mmHg, ongoing fluid resuscitation and/or requirement for inotropic support to maintain MAP at or above normal for age - does not include CPP based inotropic support. IVF alone does not exclude from enrollment. Uncorrected coagulopathy at the time of bone marrow harvest defined as INR > 1.6, PTT > 38 sec; PLT< 100,000; Fibrinogen < 100 g/dL. Unstable pelvic fractures defined as requiring early operative fixation. Pulmonary contusions defined as a chest x-ray with non-anatomic opacification and/or PaO2:FiO2 ratio < 250 associated with the mechanism of injury. Greater than AAST Grade 3 solid or hollow visceral injury of the abdomen and/or pelvis as diagnosed by CT or other imaging. Spinal cord injury diagnosed by CT/MR imaging or clinical findings. Persistent hypoxia defined as SaO2 < 94% for > 30 minutes occurring at any time from hospital admission to time of consent. Positive pregnancy test, if applicable. Concurrent participation in an interventional drug/device research study. Unwillingness to return for follow-up visits. Contraindications to MRI. Penetrating brain injury.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles S Cox, Jr., M.D.
Organizational Affiliation
The University of Texas Health Science Center, Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
Phoenix Children's Hospital I University of Arizona
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85006
Country
United States
Facility Name
The University of Texas Health Science Center at Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury

We'll reach out to this number within 24 hrs